Podcasts about Cart

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss the incidence of acute symptomatic seizures during CAR T-cell therapy.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213535   

Ken and Anthony tell you the three worst words you can hear in the summer and talk through Lima abandoning the game.

The three worst words of summer: Cart path only+Mary Kay Cabot: Shedeur speeding is not a great look in midst of 4-way QB battle+What's the best path at QB to ensure Stefanski, Berry keep their jobs?

Dr. Jeff Ratliff talks with Dr. Brin E. Freund about the evaluated incidence and risk factors for acute symptomatic seizures during CAR T-cell therapy. Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.

In this episode of The Influence Factor, Alessandro Bogliari chats with Alanah Joseph, Head of Creator Partnerships at HubSpot. Alanah shares how creator partnerships are evolving, why community is key in podcasting, and strategies to grow and monetize a podcast. From networking and consistent publishing to leveraging newsletters, she offers practical insights for creators and brands alike.

Send us a textThis episode we sit down with Dr. Akhavan, Physician Scientist at The University of Kansas Cancer Center, to dive deep into the promising world of CAR T-cell therapy. Dr. Akhavan breaks down how this innovative treatment is being applied in the brain cancer space, what patients and families need to understand about its potential and limitations, and why quality of life remains a critical part of the conversation. Whether you're newly navigating a diagnosis or seeking new hope in treatment options, this episode is packed with valuable insight, empathy, and education.Support the showRare Enough is a podcast powered by Head for the Cure, sharing real stories of resilience, hope, and community from those facing brain tumors and the people who walk beside them. Subscribe, listen, and share, because every story matters, and no one should face brain cancer alone. Follow on Instagram @RareEnoughPodcast Learn more at BrainsfortheCure.org

One of my clients just had a $63,000 launch with an almost 9% conversion rate - but honestly? The money is the least exciting part of this story. What she really achieved was proving to her nervous system that success doesn't require chaos. I work with a lot of women who have been responsible for others from a young age - incredible problem-solvers who thrive in chaos. In business, this often translates to overcomplicating everything because complexity feels safer than simplicity. But what happened when we focused her entire launch strategy on ONE thing - her waitlist - changed everything. In this episode, I'm breaking down exactly how this waitlist strategy works, why 85% of her sales came from focused effort, and the nervous system breakthrough that was more valuable than any dollar amount.In this episode, I share:

The microbiome is emerging as a key player in the effectiveness of CAR-T therapy, and today, Dr. Melody Smith, Assistant Professor of Medicine at Stanford University, sheds light on this fascinating intersection. Join us as we explore how advancements in CAR T-cell therapy are reshaping patient demographics and treatment approaches. Dr. Smith will discuss the implications of genetic engineering techniques like CRISPR, the importance of a multidisciplinary treatment strategy, and the role of antibiotic stewardship in optimizing outcomes. With insights into innovative therapies and ongoing clinical trials, this conversation promises to deepen your understanding of CAR-T therapy and its complexities, offering a glimpse into the future of cancer treatment. Read Transcription CME Information: https://stanford.cloud-cme.com/medcastepisode107 Claim CE: https://stanford.cloud-cme.com/Form.aspx?FormID=3392

An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Societyfor Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508

A Cirrus with fluctuating fuel flow, de-injecting an engine, and fear of overhaul are on tap for this episode. Email podcasts@aopa.org for a chance to get on the show. Join the world's largest aviation community at aopa.org/join Full notes below: Joe has a Maule with a 540 engine in it. The company has a mod to turn the engine to a carbureted version and he's wondering about the legality of something like that. Paul said it happens in the 210 market. Whether it's a good idea is another issue, the hosts say. Joe is unable to run autofuel is the injected version, which is why he's interested in it. Colleen said she'd rather have an injected engine than run mogas.   David wonders how perspective owners are so afraid of TBO. He has a 182 with an engine that's nearly at TBO, and people who contact him are afraid of the high time. The hosts discuss strategies for buyers who may be looking at airplanes with engines at TBO. Assuming the engine is running well, a new owner can fly it on that “borrowed time” while they learn and enjoy the airplane. Alternatively, if the engine truly needs to be overhauled, the time down is obviously a concern for a new owner. Mike said he thinks it's best to buy an airplane with a run-out engine. The price has been discounted for the cost of the engine, the seller is motivated, and worst case you have to overhaul it soon. And every hour and year that you don't have to overhaul it is “free.” And when it does come time to do the overhaul, you get to do it to your spec.   Shalom has a Cirrus that isn't behaving. If he sets the mixture at lean of peak, the fuel flows start to fluctuate. A few minutes later, it will drop off sharply, and then back quickly. The manifold pressure and rpm stay pretty consistent. He's changed the fuel pump and the spider. Nothing has helped. Mike said if there's a constriction in the fuel line between the fuel control unit and the manifold, it can cause oscillating fuel flow and lower flows.

Broadcast from KSQD, Santa Cruz on 6-12-2025: Dr. Dawn opens with alarming news about NIH budget cuts devastating cancer research just as breakthrough CAR-T cell therapy shows promise for gastrointestinal cancers. This personalized immunotherapy extracts patients' T cells, engineers them to target specific cancer antigens, and makes them essentially immortal before reinfusion. While previously successful only for blood cancers like leukemia and lymphoma, researchers achieved tumor shrinkage in 25% of solid GI tumor patients. However, devastating layoffs forced removal of two patients from trials due to staff shortages and supply chain disruptions. Dr. Dawn emphasizes how pregnancy can worsen hidden cancers due to immune suppression, explaining why aggressive metastasized cancers often appear shortly after childbirth. Dr. Dawn takes a call from Bob about concerning forehead growths his dermatologist examined. She speculates they're likely seborrheic keratoses - benign, stuck-on appearing growths common in sun-exposed areas that look like crumpled brown paper "spit-wads". These aging-related changes are harmless and can even be picked off, though she warns against repeatedly traumatizing any skin area as this increases cancer risk through accumulated DNA damage. She explains how repetitive trauma in occupational settings creates statistically higher cancer risks, comparing it to filling a bingo card of cellular errors. She addresses an email about Joe Tippens' cancer cure protocol involving fenbendazole, an anti-parasitic drug. Dr. Dawn explains this viral social media phenomenon began when Tippens claimed his lung cancer was cured by fenbendazole, but he was simultaneously receiving Keytruda immunotherapy at MD Anderson. The story spread rapidly in South Korea, causing pharmacy shortages. Unvalidated internet health information can spread dangerously. Dr. Dawn compares it to old-fashioned medicine show scams. trend Dr. Dawn warns about a recent vitamin B6 toxicity misdiagnosis trend affecting her patients who were told they had dangerous levels of B6 despite lacking neuropathy symptoms. Accuracy requires fasting 12 hours before blood draws, otherwise creating false elevations from recent vitamin consumption. More critically, she alerts listeners about biotin(Vitamin B7) interference with laboratory tests using biotin-streptavidin techniques. High-dose biotin supplements are often used in hair and nail health growth formulas. This can falsely alter tests for thyroid hormones, vitamin D, sex hormones, cortisol and dangerously, troponin levels that diagnose heart attacks. This could lead to missed myocardial infarctions in emergency rooms, potentially causing fatal outcomes. Dr. Dawn takes a call from Richard seeking information about a previous radio program guest. She guides him to use on-line resources at ksqd.org to find program details, pivoting into praise for libraries as community centers offering far more than internet access. She emphasizes libraries provide serendipitous discovery that algorithms can't match, encouraging people to explore their local library systems for events, historical collections, and personal assistance from knowledgeable librarians eager to help visitors navigate both physical and digital resources. She discusses the concerning trend of giving melatonin to children, calling it "the Grinch that stole children's bedtime." While used prescription-only for severe developmental disorders in Denmark and EU countries, American children receive melatonin gummies regularly, with one in five preteens using it occasionally. Dr. Dawn explains melatonin is a hormone affecting pancreas, heart, fat tissue, and reproductive organs still developing in children. Supplemental doses create blood levels 10 times higher than natural peaks, representing an uncontrolled medical experiment on developing brains and bodies. Poison control calls for melatonin ingestion increased 530% between 2012-2021, with one tragic case involving a three-month-old death where 20 melatonin bottles were found in the home. Dr. Dawn concludes by debunking food expiration date myths, explaining that Americans waste a third of food ($7 billion annually) due to misunderstanding labels. Most shelf-stable foods simply degrade in quality rather than becoming dangerous after printed dates. She notes acidic dairy products like yogurt resist bacterial contamination due to protective bacteria,and even surface mold can be scraped off safely. However, she emphasizes trusting expiration dates on lunch meats and deli products, which pose real listeria risks when stored improperly. California will soon simplify labeling laws to reduce confusion between quality and safety dates.

We start off with some good old spaceweather news, which leads into a discussion of the Earth's rapidly weakening magnetic field and the possibility of a polarity flip. We then move on to some discussion of further observations on the construction of pyramids and new things we learned in our recent trip in Egypt.In the second half of the show, we talk about the amazing cart ruts we visited in the Phrygian Valley in Turkey. We show lots of pictures and video, and discuss and discard multiple hypotheses on what they are and how they were formed.Join us, Ben from UnchartedX, Adam Young, and Karoly Poka for an afternoon at The Metropolitan Museum of Art in New York where we will peruse their collection of Ancient Egyptian artifacts, then we will move to the Explorer's Club for dinner and presentations from us and Ben!https://eveningattheexplorersclub.eventbrite.com/Join our Patreon, support the show, get extra content and early access!https://www.patreon.com/brothersoftheserpentSupport the show with a paypal donation:https://paypal.me/snakebros

In today's episode of Inside Kingston we talk about the updates on shelter services in the city, Robert Bruce Memorial Parking Garage Public Art, a preview of the upcoming council meeting, pride month, a change in the LaSalle Causeway lift schedule, an update on cart-based waste collection and an upcoming Giveaway day. You can learn more about everything mentioned in this week's episode here: ✨Shelter services - https://getinvolved.cityofkingston.ca... ✨Public art - https://getinvolved.cityofkingston.ca... ✨City Council meetings - https://www.cityofkingston.ca/council... ✨Pride - https://www.visitkingston.ca/your-gui... ✨LaSalle Causeway Lift - https://www.canada.ca/en/public-servi... ✨Cart-based Waste Collection - https://www.cityofkingston.ca/garbage... ✨Giveaway day - https://www.cityofkingston.ca/news/po...

Drs. Lipsky and Allan discuss the emerging role of immunotherapy in the management of patients with CLL, including CAR T-cell therapy and bispecific antibodies.

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Cleveland, OH What's changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don't miss this dynamic conversation packed with expertise and hope for the future of AML!

Pole Vault U. Don't take that nap. State of Beverages report. Soda stats. Moving sidewalks might be on the way out. High school experiences. Jokes with Sean. Bacon news. Winner! Trademark wars. Pizza Vodka. Bar tabs.

The Bridle, the Cart, and the Carthorse.

This week Shauna and Dan try not to upset the apple cart. Bonus: The USA's earliest pen pals, wizardly cats, and Gudrun Lauret's disruptive creators (or possibly creative disruptors) It's free to join our Patreon, patreon.com/bunnytrailspod On our Patreon you have direct access to reach Shauna and Dan, plus join our weekly chats and polls. Paid tiers have even more perks, like early access and name recognition on the show. So join us on Patreon! patreon.com/bunnytrailspod Shownotes are always available on our website, bunnytrailspod.com Copyright 2025 by The Readiness Corner, LLC - All Rights Reserved  

In this episode of Careers in Discovery, we're joined by Markus Gruell, Senior Vice President of Corporate Quality at Autolus, one of the UK's leading CAR-T therapy pioneers. Markus takes us behind the scenes of Autolus' journey from a UCL spinout to a commercial-stage Biopharma company, offering a rare look at how quality underpins every part of the drug development lifecycle. From working across GMP and GCP to collaborating with regulators on novel therapies, Markus shares what it means to lead quality in a fast-moving, high-growth Biotech business. We also explore Markus' personal journey - from pharmacist to QP, and from the NHS to senior leadership - guided by a passion for learning, a commitment to patient safety, and a belief in empowering his team through empathy and integrity. If you're curious about CAR-T, what quality looks like in a next-gen therapy company, or how to build a meaningful leadership career without a traditional plan, this episode is not to be missed.  

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. David Akhavan, a physician-scientist pioneering cell therapy research for brain cancer. Dr. Akhavan discusses the revolutionary potential of chimeric antigen receptor (CAR) T-cell therapy in treating cancers like glioblastoma, the complexities involved and the innovative approaches his team is employing, such as smarter engineered T-cells and nanoparticles. Highlighting the collaboration within KU Cancer Center, Dr. Akhavan also shares personal insights into his motivation and the future of cancer treatment. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about cell therapy at KU Cancer Center Learn more about brain cancer Read more about Dr. Akhavan's work on the KU Cancer Center blog, “Exploring Immunotherapy Treatments to Treat Brain Cancer” Learn about Head for the Cure Read how physician-scientists at KU Cancer Center bridge the gap between the laboratory and the clinic  

In this hilarious and unfiltered episode, Donna and Brittney Boo are joined by returning guest and cart cutie Nathalie for a deep dive into the wild world of the beverage cart. It's time for confessions, cocktails, and the colorful cast of characters they encounter every week on the course.Brought to you by our favorite beverage cart experts (and cuties), Brittney Boo & Nathalie, this episode covers:*The wildest moments from the Kachina Men's Invitational at Alta Mesa*Best customer of the week, worst attitude, and a few touching moments of kindness*The top 3 most-ordered drinks right now*Donna's new favorite summer cocktail*What your drink says about your golf game (you'll either laugh—or feel very seen)*Cart-side fashion breakdowns: who's nailing the look, who's missing the mark, and a few surprises that somehow worked*A quick tip from Donna on how to balance style and function on the courseThe players who show up to slay, not score—and why we love them for itWe wrap up with Cart Confessionals (yes, they're juicy!) and break down the formats from the Alta Mesa Member-Guest: scrambles, best balls, Calcutta, horse race, and the classic ham and egg strategy.This episode is all fun, flavor, and fairway chaos—a true look into the day in the life of the beverage cart crew.Big thanks to our amazing listeners—old and new—for tuning in!Please keep sharing Golf Party Live with your golf girlfriends (and guy friends too).And we'd love to hear from you—what's your go-to cocktail on the course or at the 19th hole? Drop us a message or tag us in your favorite drink pics!

In this episode, Heather and Matthew welcome Dr. Leonardo Ferreira, Assistant Professor at the Medical University of South Carolina and cofounder of Torpedo Bio. Leo shares how his team at Torpedo Bio  is working to develop safe and effective cellular immunotherapy for solid tumors. We have an exciting conversation on the promise of CAR-T therapy, the challenges life sciences startups face, and how federal research funding impacts innovation. Tune in to hear how Torpedo Bio is pushing the boundaries of cancer treatment!

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, involving 583 episodes of progression, found that simultaneous confirmation of disease progression using two different markers (e.g., serum protein electrophoresis and serum free light chain assay) was 98% accurate, compared to 82% for sequential confirmation. This suggests that simultaneous confirmation could improve clinical trial accuracy and reduce false censoring. The International Myeloma Working Group is set to revise its response criteria to incorporate these findings, potentially simplifying disease assessment and reducing the need for multiple blood draws.

In this episode of Better Edge, Northwestern Medicine Neurologist Shailee Shah, MD, and Neuro-oncologist Ditte Primdahl, MD, unpack the latest advancements in paraneoplastic syndrome management, highlighted at the 2025 American Academy of Neurology Annual Meeting.   Together, they explore: The complex interplay between immune checkpoint inhibitors and autoimmune neurologic syndromes Emerging therapies, including CD19-directed CAR T-cell treatments Updates to diagnostic criteria and risk stratification using high-risk autoantibodies The role of predictive biomarkers and advanced omics in diagnosis The launch of a dedicated paraneoplastic clinic at Northwestern Medicine

Recapping Season 8 Epsiodes 3 & 4 Amanda and Maggie are two silly ladies who have made plenty of silly mistakes. Amanda wins the mistake trophy for this season because she just completely skipped over an epsiodes and didn't edit or release it in time! HUGE shout out to listener (maybe their BFF?) Georgia for writing in to let them know she couldn't find this episode. So kind of her to call them in for their mistake while they shout it from the rooftops how thankful they are you let them know. Who knows how many thousands of you would have missed this little delight in your ears? Thanks, Georgia! (Also please leave a review if you haven't!):)  In this episode, the girls decide which one of Maggie's kids represents members of the firm, they have a very brief discussion about Star Trek, all while juggling a wild thunderstorm and Whisky the Producer Dog's reaction to all that noise.  For all things OSF, visit onlysuitsfans.com   

We start off with some good old spaceweather news, which leads into a discussion of the earth's rapidly weakening magnetic field and the possibility of a polarity flip. We then move on to some discussion of further observations on the construction of pyramids and new things we learned in our recent trip in Egypt. In the second half of the show, we talk about the amazing cart ruts we visited in the Phrygian Valley in Turkey. We show lots of pictures and video, and discuss and discard multiple hypotheses on what they are and how they were formed.   Join us, Ben from UnchartedX, Adam Young, and Karoly Poka for an afternoon at The Metropolitan Museum of Art in New York where we will peruse their collection of Ancient Egyptian artifacts, then we will move to the Explorer's Club for dinner and presentations from us and Ben! https://eveningattheexplorersclub.eventbrite.com/ Join our Patreon, support the show, get extra content and early access! https://www.patreon.com/brothersoftheserpent Support the show with a paypal donation: https://paypal.me/snakebros   Chapters 00:00 Welcome to Brothers of the Serpent 02:01 Space Weather News 05:32 Earth's Magnetic Field Dynamics 10:05 Geomagnetic Excursions and Their Implications 15:49 Magnetic Field Weakening and Its Consequences 20:08 Mars, Venus, and Planetary Magnetic Fields 24:22 Life on Other Planets: The Case of Europa 28:08 Life in Extreme Environments 29:51 Theoretical Life Forms and Energy 31:21 Science Fiction Inspirations 33:35 Podcast Reflections and Communication Barriers 34:35 Debating Ancient Structures 37:43 Pyramid Construction Insights 39:20 The Anatomy of Pyramids 42:30 Theories on Pyramid Design 50:30 Mythology and Historical Interpretation 58:24 Exploring the Met and Event Details 59:08 The Mystery of Cart Ruts 01:01:03 Colonial Cart Ruts: A Historical Perspective 01:03:20 Investigating Turkish Cart Ruts 01:06:03 Analyzing the Characteristics of Ruts 01:09:12 Theories on Rut Formation 01:12:32 Erosion and Its Impact on Ruts 01:15:58 The Case for Hand-Carved Ruts 01:19:20 Challenging Conventional Explanations 01:27:59 Concluding Thoughts on Cart Ruts 01:29:25 Exploring the Mechanics of Ruts 01:36:00 Drone Footage Insights 01:43:11 The Mystery of Disappearing Ruts 01:50:06 Theories and Speculations on Cart Ruts

These lectures will explore two Arthurian romances, Chretien de Troyes' Knight of the Cart, and the Cistercian text we know as The Quest of the Holy Grail, through the lens of Catholic teaching on redemption, divine grace, and the pursuit of virtue.

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University Health Stephenson Cancer Center and serves as an ambassador for ASCO. The group highlighted several late-breaking abstracts, plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following: ·       Phase 1b/2 CARTITUDE-1 trial (NCT03548207, NCT05201781) o   Long-term follow-up showed that approximately one-third (33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti).  o   An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas. o   With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-not evaluable [NE]). ·       Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use o   Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma. o   Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. o   Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings. ·       Phase 1b/2 NEXICART-2 trial (NCT06097832) o   Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options. o   Among 12 patients who received the agent at 450 x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively.  o   With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred. References 1. Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.7507 2. Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.7023 3. Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508. doi:10.1200/JCO.2025.43.16_suppl.7508

In this special episode (#34) of BioTalk Unzipped, recorded live at the AAPS NBC conference in Boston, Gregory Austin and Dr. Chad Briscoe sit down with AAPS President Dr. Russ Weiner for an unfiltered look inside AAPS NBC, at the state of rare disease research, the evolution of therapeutic modalities, and the human stories that drive scientific innovation.From navigating the emotional weight of personal loss to watching his son experience the field firsthand, Russ shares not only his scientific insights but the heart behind his leadership. The conversation spans topics like the rising promise of AI diagnostics, challenges with biomarker sampling logistics, the role of CROs in rare disease trials, and the future of autologous vs. allogeneic therapies.Dr. Weiner also offers an inspiring vision of industry collaboration, sharing how organizations like AAPS are becoming conduits for progress across low- and middle-income countries, underrepresented diseases, and emerging biotechnologies. Whether you're in the lab, the boardroom, or on the frontlines of clinical trials, this episode will reignite your sense of purpose in this field.00:00 Preview & Intro01:22 What is conference life like as AAPS President02:27 Mentoring & Fatherhood at AAPS03:54 Setting up the Meeting Season for AAPS05:43 Life back in the Rare Disease Space - a Passion10:58 The different costs of pharmaceutical & biotech research12:59 The generosity of Rare Disease Patients14:41 Dr. Chad Briscoe asks Russ what can we do to help advance Rare Disease efforts19:57 Rare Disease conversations happening at AAPS and global reach22:37 Broad use of new technologies, including Olink24:10 Biggest change expected in Pharma in 10 yearsDr. Russ Weinerhttps://www.linkedin.com/in/russellweiner/ AAPS - https://www.aaps.org/home Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/ Takeaways:Treating rare diseases early is not only life-saving—it's economically sound. Gene and cell therapies may carry high price tags, but they dramatically reduce long-term costs.The diagnostic delay for rare diseases—often 4 to 7 years—remains one of the biggest barriers to treatment. AI-powered diagnostics and data integration could change that.Dr. Russ Weiner shares how personal loss fueled his career in science and how mentoring the next generation, including his son, brings it full circle.The shift toward allogeneic cell therapies and in vivo CAR-T treatments will be key to driving down costs and increasing global accessibility.CROs must evolve: future-ready organizations will localize biomarker analysis and forge relationships with rare disease investigators to improve site performance.Technologies like Olink are revolutionizing biomarker discovery, enabling cost-effective, high-resolution multiplexing that was previously out of...

Episode 237 This episode has stories about lost items, telepathy, Korea, beverage carts, Sri Lanka and a backpack nazi. Contact... flywithbetty@gmail.com The Telepathy Tapes Ravens Cup Coffee and Art Gallery, La Conner, WA Let's Talk Off Camera My website Patreon Instagram:Bettyinthesky Twitter: Skybetty My Amazon page

This week's topics include treating hot flashes in breast cancer survivors, a blood test for detecting colorectal cancer, exercise to improve survival after colorectal cancer treatment and CAR-T therapy for solid tumors.Program notes:0:40 CAR-Ts for solid tumors1:40 Advanced gastric or gastroesophageal cancer2:40 Cytokine release syndrome3:22 Exercise after treatment for colorectal cancer4:23 Disease free survival superior5:23 Currently not much exercise6:23 Potential mechanisms7:10 Treating hot flashes in breast cancer survivors8:10 Neurokinin receptors9:12 A blood test to screen for colorectal cancer10:12 Asymptomatic adults11:12 Will not replace FIT or screening colonoscopy12:12 Survival advantage due to polypectomy13:19 End

Get a copy here: freeleaguepublishing.com/games/dragonbane/ Music Attribution: Theme: Black Vortex by Kevin McLeod Follow us!

 --www.TheatreMindPlay.com --FB: bit.ly/MindPlayersFB
 --Insta: bit.ly/MindPlayersIG
 --Twitter: bit.ly/MindPlayersTw 
--Twitch: bit.ly/MindplayersTwitch
 --YouTube: bit.ly/MindPlayersYT
 --Patreon: bit.ly/MindPlayersPat

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Fired employees from the Department of Health and Human Services are suing Robert F. Kennedy Jr. and Elon Musk, claiming their terminations were based on inaccurate and error-ridden information. The lawsuit alleges that HHS leadership knew the records used to guide layoff decisions were flawed. UniQure's regulatory progress has sparked optimism for Huntington's disease patients, with analysts reacting positively to the company's accelerated approval pathway for a gene therapy submission in 2026. Cullinan has made a back-heavy deal in China worth over $700 million for autoimmune T cell engager technology, while Sarepta has won FDA's platform technology designation for gene therapy development. Rapt is shrinking after discontinuing a drug, agileAD is gearing up to challenge J&J in the multiple myeloma Car-T market, and Lilly has signed a deal for long-acting obesity drugs.

Uma manhã com análises detalhadas ao agarrão do Presidente da República e até o Markl quase falou de futebol!

In this week's episode, we'll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.Featured Articles:Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Jefferies predicts an increase in small tuck-in deals in the biotech industry as companies face challenges accessing capital. Companies and industry groups are offering solutions to mitigate the impact of Trump tariffs on rare disease, cell, and gene therapy. Pitchbook suggests a shift towards more sustainable investing in biotech VC firms. Gilead is gearing up to challenge J&J in the $20 billion multiple myeloma CAR-T market. PTP's generative AI is revolutionizing data summaries for biotech QC workflows. Sanofi recently acquired Blueprint for $9.5 billion, while BMS has committed up to $11 billion with Biontech. Lilly has signed a deal worth up to $870 million, and Regeneron is investing nearly $2 billion in a Chinese obesity drug. Merck's CEO is emphasizing diversity in operations following the defeat of an anti-DEI measure. Immuno-oncology drugs Keytruda and Opdivo may face scrutiny in the near future.In other news, Vigil Neuroscience's Trem2 antibody for a rare brain disease failed in a Phase II trial shortly after Sanofi's acquisition of the company. Analysts believe the results were not surprising and should not impact the deal. Lilly has signed a deal worth up to $870 million to develop a long-acting GLP-1 obesity drug, while the FDA is committed to making rare disease drugs available at the first sign of promise. Pharma tuck-in deals are increasing after a slow first quarter for small biotechs. BioAgc Biologics will be attending Bio International in Boston to discuss their global drug production capabilities.Stay tuned for more updates on investing in research, welcoming global talent, the biotech VC cycle, Gilead's challenge to J&J in the multiple myeloma CAR-T market, and much more. Upcoming events and job listings in the pharmaceutical industry are also featured in our newsletter.Thank you for tuning in to Pharma and Biotech daily.

Cart and Deion's post-NBA draft deadline top 10! Drafting the scariest college basketball coaches to recruit against! Drafting college basketball's most talented rosters! The Sleepers Podcast is now available daily with new episodes every Monday-Friday!

Agés respectivement de 23 et 45 ans, Vanina et Gregory sont en couple depuis 3 ans. Ils se sont rencontrés dans un cadre assez atypique : l'autoécole ! Grégory était le moniteur de Vanina. Le coup de foudre a été immédiat pour Gregory et Vanina a mis guère plus de temps avant de craquer également !Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Marcos de Lima, hematologist-oncologist at The OhioState University Comprehensive Cancer Center, to explore the rapidly evolving field of homegrown CAR-T therapies. Together, they dive into the definitions, motivations and barriers of decentralized CAR-T manufacturing, the globalinnovation landscape and what it takes to build sustainable academic cell therapy programs. Dr. de Lima shares his firsthand experience launching point-of-care CAR-T programs, the regulatory and payer landscape and the future of academic-industry collaboration in expanding access. It's a must-listen for anyone interested in the future of decentralized cell therapy and innovation in academic centers.

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

In China's cutthroat e-commerce battleground, every 'Add to Cart' triggers a cascade of costs—layered, opaque, and ever-changing. But who ultimately pays the price? We unravel the hidden world of platform fees and decode what China's draft regulations mean for merchants, marketplaces, and the millions of shoppers caught in the crossfire. On the show: Heyang, Steve Hatherly & Yushun

In this episode of It Takes Balls, Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care explores everything from recurrence and refractory disease to the latest advancements in treatment and monitoring.Dr. Adra breaks down risk categories that guide treatment - good, intermediate, and poor - and explains how factors like tumor type and blood markers shape decisions about chemo, surgery, or surveillance. He also dives into the science behind relapse and platinum resistance.A major highlight of the episode is the discussion of innovative diagnostic tools like circulating tumor DNA (ctDNA) and microRNA-371. These biomarkers are making it possible to detect microscopic cancer earlier and more accurately, with the goal of reducing overtreatment and improving outcomes.Dr. Adra also shares insights on long-term monitoring, including the reality of late relapse, and emphasizes why annual checkups are crucial - even decades after treatment. For those with relapsed or refractory disease, he offers a hopeful look at cutting-edge therapies including targeted treatments, high-dose chemo, and upcoming CAR-T cell trials.Have a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgEmail Dr. Adra:nadra@iu.eduFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

In this episode of The Influence Factor, Alessandro Bogliari speaks with Courtney Weis, Managing Director of Brand Marketing at FP Movement. Their conversation explores the brand's commitment to empowering women through activewear, the vital role of community involvement, and the dynamic shifts within influencer marketing. Courtney offers valuable perspectives on FP Movement's collaborations with athletes and creators, highlights the power of storytelling in brand marketing, and provides a preview of the brand's upcoming campaigns and activations.

This week we revisit Sherry Cola stepping straight out of the big screen into the Add to Cart universe. The “JOY RIDE” actress reflects on the importance of seeing Asian women fully represented as their wild, raunchy and hilarious selves. In the spirit of being true to yourself, Sherry dishes on her favorite Asian snacks and why her Hello Kitty subscription box is self-care. She also shares how she’s finding her zen, and why she’s removing from cart saying “yes” (but not to this podcast!) Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. Sherry is healing her inner childhood with the Hello Kitty subscription box Her fave Asian snacks now are IRVINS Salted Egg Potato Chips Crisps and the classic wasabi peas ATC faves are Chingoo snacks and Loaf Language JOY RIDE is in theaters now! Randall Park’s movie Shortcomings (starring Sherry Cola) will be in theaters August 4 Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia. Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium. Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: lemonadamedia.com/sponsorsSee omnystudio.com/listener for privacy information.

This month, the gals are visited by Cassidy Liston from Drinking the Koolaid Podcast to discuss gull shrieking, mystery man meats, angel eggs, red-wing red flags, crystal-encrusted corpses, and a suspiciously bound book. Tune in for May's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.